Deal Snapshot: Pipeline gets $50m up front and a $25m equity investment in exchange for global rights to an M1 receptor antagonist cleared to move into Phase II in relapsing/remitting MS.
Who: Johnson & Johnson/Pipeline Therapeutics
What: J&J obtains worldwide licensing rights to Pipeline’s PIPE-307, a Phase I candidate ready to move into Phase II
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
An ‘historic economic prosperity deal’ does not include the sector.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
An ‘historic economic prosperity deal’ does not include the sector.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
